Send me real-time posts from this site at my email

H.C. Wainwright Thinks InflaRx’s Stock is Going to Recover

H.C. Wainwright analyst Edward White maintained a Buy rating on InflaRx (IFRXResearch Report) today and set a price target of $10.00. The company's shares closed last Monday at $2.53, close to its 52-week low of $2.23.

According to, White is a 5-star analyst with an average return of 24.2% and a 43.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for InflaRx with a $2.50 average price target.

See Insiders’ Hot Stocks on TipRanks >> Based on InflaRx's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.78 million. In comparison, last year the company had a GAAP net loss of $10.03 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany. Read More on IFRX:

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue